At present, PCSK9 inhibitors are recommended for patients with familial hypercholesterolemia and secondary prevention of high-risk patients who fail to reach the LDL-target despite optimal treatment or those intolerant to statins [4]. Here, PCSK9 is linked to familial hypercholesterolemia.